The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and ...

A new study found that GLP1-RA medications may help lower the risk of a cardiovascular event in people with type 2 diabetes. Getty Images GLP-1 medications commonly prescribed for weight loss, like ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...

B y now, you’ve likely heard of GLP-1 and dual GIP/GLP-1 receptor agonist medications (which stands for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) that can help you lose ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) ...

Taking magnesium with a GLP-1 like Ozempic? Learn how they can interact, potential digestive effects, and key safety tips.